UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13D

(Rule 13d-101)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(a)

 

Under the Securities Exchange Act of 1934

(Amendment No. 12)*

 

Abcam plc

(Name of Issuer)

 

Ordinary Shares

(Title of Class of Securities)

 

000380204

(CUSIP Number)

 

Jonathan Milner

Honey Hill House, 20 Honey Hill

Cambridge CB3 0BG

 

With copies to:

 

Richard M. Brand

Cadwalader, Wickersham & Taft LLP

200 Liberty Street

New York, NY 10281

212-504-6000

Michael Newell

Cadwalader, Wickersham & Taft LLP

100 Bishopsgate

London EC2N 4AG

44 (0) 20 7170 8540

 

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

September 28, 2023

(Date of Event Which Requires Filing of This Statement)

 

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. x

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1  

NAME OF REPORTING PERSON

Dr. Jonathan Milner

2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) x

 

 

3  

SEC USE ONLY

 

 

4  

SOURCE OF FUNDS

 

PF (See Item 3)

 

5  

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

 

 

6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United Kingdom

 

Number of

shares

beneficially

owned by

each

reporting

person

with

 

 

   7  

SOLE VOTING POWER

 

11,745,4001

 

  8  

SHARED VOTING POWER

 

2,410,8022

  9  

SOLE DISPOSITIVE POWER

 

11,745,4001

 

  10  

SHARED DISPOSITIVE POWER

2,410,8022

 

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

14,156,2021, 2

 

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨

 

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

 6.15%*

 

14  

TYPE OF REPORTING PERSON

 

IN

 

             

* All percentage calculations set forth herein are based upon the aggregate of 230,148,147 Ordinary Shares as of August 31, 2023, as disclosed in Form SH01 filed at the Companies House of the United Kingdom on September 21, 2023.

1 Includes 11,700,200 Ordinary Shares directly held by the Reporting Person and 45,200 shares directly held by the Reporting Person through American Depository Shares representing, each, one Ordinary Share (“ADS”).

2 Includes 399,382 ADSs held by the Reporting Person’s spouse, 1,977,967 ADSs held by three limited companies over which the Reporting Person exercises investment discretion and 33,453 ADSs held by a charitable trust to which the Reporting Person is a trustee and signatory. The Reporting Person disclaims beneficial ownership over the shares beneficially owned by his spouse, except to the extent of his pecuniary interest therein.

 

 

 

 

This Amendment No. 12 to Schedule 13D (this “Amendment No. 12”) amends and supplements the Schedule 13D filed on May 1, 2023, as amended and supplemented on May 18, 2023, May 30, 2023, June 5, 2023, June 6, 2023, June 12, 2023, June 20, 2023, June 21, 2023, June 23, 2023, June 27, 2023, August 16, 2023 and September 14, 2023 (the “Original 13D,” and as amended and supplemented by this Amendment No. 12, the “Schedule 13D”) by the Reporting Person, relating to the Ordinary Shares of the Issuer. Except as specifically provided herein, this Amendment No. 12 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms not defined in this Amendment No. 12 shall have the meaning ascribed to them in the Original 13D.

 

The purpose of this Amendment No. 12 is to update the disclosure in Items 4, 5 and 7 of the Schedule 13D as hereinafter set forth.

 

ITEM 1. SECURITY AND ISSUER

 

This statement on Schedule 13D relates to the Ordinary Shares of the Issuer. The principal executive offices of the Issuer are located at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom.

 

ITEM 2. IDENTITY AND BACKGROUND

 

(a), (f) This statement is being filed by Dr. Jonathan Milner, a citizen of the United Kingdom.

(b) The address of the Reporting Person is Honey Hill House, 20 Honey Hill, Cambridge, CB3 0BG.

(c) The Reporting Person’s principal occupation is as an investor and executive in life sciences companies.

(d), (e) During the last five years, the Reporting Person (i) has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and (ii) was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

 

ITEM 4. PURPOSE OF TRANSACTION

 

Item 4 is hereby amended to add the following:

 

On September 28, 2023, the Reporting Person published his Proxy Statement, for the forthcoming court meeting, as set forth more fully in Exhibit 99.18 hereto. 

 

On September 28, 2023, the Reporting Person published a press release regarding the Issuer, as set forth more fully in Exhibit 99.19 hereto. 

 

ITEM 5. PURPOSE OF TRANSACTION

 

Item 5 of the Schedule 13D is hereby amended and restated as follows:

 

(a) The Reporting Person is the holder of 11,700,200 Ordinary Shares and 45,200 ADSs. In addition, the Reporting Person may be deemed to share beneficial ownership over (a) 1,977,967 ADSs beneficially owned by three limited companies over which the Reporting Person exercises investment discretion, (b) 399,382 ADSs beneficially owned by the Reporting Person’s spouse and (c) 33,453 ADSs held by a charitable trust to which the Reporting Person is a trustee and signatory. The Reporting Person disclaims beneficial ownership over the shares beneficially owned by his spouse, except to the extent of his pecuniary interest therein. The shares described in this Item 5 represent approximately 6.15% of the outstanding Ordinary Shares

 

(b)

 

  (i) Sole power to vote or to direct the vote: 11,745,400

 

  (ii) Shared power to vote or direct the vote: 2,410,802

 

  (iii) Sole power to dispose or to direct the disposition of: 11,745,400

 

  (iv) Shared power to dispose or to direct the disposition of: 2,410,802

 

(c) See Schedule IV, which is incorporated herein by reference, describes the transactions by the Reporting Person in the Common Stock during the past sixty days.

 

(d) N/A

 

(e) N/A

 

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

 

Item 7 is hereby amended to add the following exhibits:

 

Exhibit 99.18 Proxy Statement dated September 28, 2023.
Exhibit 99.19 Press Release by Jonathan Milner, dated September 28, 2023.

 

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: September 28, 2023

 

  By: /s/ Jonathan Milner
    Name:  Jonathan Milner

 

 

 

 

Schedule IV

 

TRADING DATA

 

The following table sets forth all transactions in the Ordinary Shares of the Issuer effected by the Reporting Person in the past 60 days. Except as otherwise noted below, all such transactions were purchases or sales of Ordinary Shares effected in the open market and the table excludes commissions paid in per share prices.

 

Reporting Person Trade Date Buy/Sell No. of
Shares/
Quantity		 Unit Cost/
Proceeds		 Security
Jonathan Milner 9/11/2023 Buy 4,500 $22.8599 ADS
Jonathan Milner 9/12/2023 Buy 4,500 $22.7899 ADS
Jonathan Milner 9/13/2023 Buy 4,500 $22.8389 ADS
Jonathan Milner 9/14/2023 Buy 4,500 $22.8172 ADS
Jonathan Milner 9/15/2023 Buy 4,500 $22.8200 ADS
Jonathan Milner 9/18/2023 Buy 4,500 $22.7244 ADS
Jonathan Milner 9/19/2023 Buy 4,500 $22.6700 ADS
Jonathan Milner 9/20/2023 Buy 4,500 $22.6500 ADS
Jonathan Milner 9/21/2023 Buy 4,500 $22.6800 ADS
Jonathan Milner 9/22/2023 Buy 4,500 $22.6000 ADS

 

 

 

 

Exhibit 99.18

 

MEETING OF SHAREHOLDERS

 

OF

 

Abcam plc

Discovery Drive

Cambridge Biomedical Campus

Cambridge CB2 0AX

 

United Kingdom (Registered in England & Wales under Company No. 03509322)

 

PROXY STATEMENT

 

DATED September 28, 2023

 

OF

 

Jonathan Milner

 

To Fellow Abcam Shareholders:

 

This Proxy Statement and the accompanying WHITE Proxy Card are being furnished to shareholders (“Shareholders”) of Abcam plc (“Abcam” or the “Company”) in connection with the solicitation of proxies by Dr. Jonathan Milner (“Dr. Milner”) to oppose the proposed acquisition by Danaher Corporation (NYSE: DHR) or one of its affiliates of all of the outstanding shares of Abcam (the “Shares”) for $24.00 per Share to be effected by means of a court-approved scheme of arrangement pursuant to the United Kingdom Companies Act 2006 (the “Companies Act”) (the “Proposed Transaction”) at meeting(s) of the Shareholders convened with the permission of the relevant courts in England and Wales under the Companies Act in connection with the Proposed Transaction, to be held at the Company’s offices at Discovery Drive, Cambridge Medical Campus, Cambridge, CB2 0AX, United Kingdom or another location to be announced by the Company, including any adjournments, postponements or continuations thereof (the “Court Meeting”).

 

Further details of the Court Meeting, and other details relating to the Proposed Transaction, will be included in a circular issued by Abcam to Shareholders in due course (the “Scheme Circular”). Dr. Milner encourages you to read the contents of the Scheme Circular when it is available as it will contain detailed information about the Proposed Transaction and the Court Meeting.

 

As more fully detailed in an open letter from Dr. Milner to you dated on or around the date hereof, Dr. Milner believes that the Proposed Transaction is poorly conceived, ill-advised and not in the best interests of Abcam or its Shareholders.

 

1

 

 

Proposal

 

As set forth more fully in this Proxy Statement, we are soliciting proxies from the Shareholders (including from the holders (“ADS Holders”) of American Depositary Shares (“ADSs”)) in respect of the following proposal to be considered at the Court Meeting:

 

THAT the scheme of arrangement to effect the acquisition by Danaher Corporation (or one of its affiliates) of shares in the Company at a price equal to $24.00 per share, such scheme of arrangement as more particularly described in a circular published or to be published by the Company (such scheme of arrangement in its original form or with or subject to any modification, addition or condition made thereto in accordance with applicable law) (the “Scheme”) and approved or imposed by a court of competent jurisdiction in England and Wales, be approved and the directors of the Company (or a duly authorised committee thereof) be authorised to take all such actions as they may consider necessary or appropriate for carrying the Scheme into effect.

 

Other Matters

 

Dr. Milner knows of no other business to be presented at the Court Meeting. If any other business should properly come before the Court Meeting, it is intended that the holder of the WHITE Proxy Card will vote that proxy on such other business in accordance with that holder’s judgment.

 

DR. MILNER URGES SHAREHOLDERS (INCLUDING ADS HOLDERS) TO VOTE THE WHITE PROXY CARD AGAINST THE PROPOSAL.

 

PLEASE NOTE THAT, IF YOUR SHARES ARE REPRESENTED BY AMERICAN DEPOSITARY SHARES AND HELD ON DEPOSIT BY CITIBANK, N.A. AS DEPOSITARY (THE “DEPOSITARY”), OR IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU WISH TO HAVE YOUR VOTES CAST AT THE MEETING, YOU MUST OBTAIN, COMPLETE AND TIMELY RETURN A PROXY CARD ISSUED IN YOUR NAME OR COMPLY WITH OTHER VOTING INSTRUCTIONS PROVIDED BY THAT INTERMEDIARY.

 

2

 

 

BACKGROUND TO THE SOLICITATION

 

·Dr. Milner founded Abcam in 1998 and became its Chief Executive Officer and a Director on the Board of Directors of Abcam (the “Board”).

 

·Under Dr. Milner’s leadership the Company enjoyed positive share performance and great scientific success, becoming the world’s leading supplier of antibodies.

 

·In 2005, Dr. Milner led the Company to listing on the London Stock Exchange.

 

·In 2014, Dr. Milner stepped down as Chief Executive Officer to facilitate an orderly succession of management leadership. By this time initial investors in the Company had experienced an extraordinary ~20x appreciation.

 

·Upon the occurrence of Dr. Milner’s stepping down, Mr. Alan Hirzel, previously the Chief Marketing Officer of the Company, was promoted to Chief Executive Officer. Dr. Milner continued as Deputy Chairman of the Board and undertook a role mentoring the new Chief Executive Officer.

 

·By 2019, the Company had grown to a market capitalization of ~$5 billion.

 

·In June 2020, Dr. Milner announced that he would not stand for reelection to the Board later that year, after what he believed to be a sufficient period of transition to new leadership.

 

·On October 21, 2020, the Company’s registration of ADSs to be traded through the Nasdaq exchange was declared effective by the U.S. Securities and Exchange Commission (“SEC”).

 

·Effective October 26, 2020, the Company executed a Deposit Agreement with Citibank, N.A. as Depositary to create a facility to hold Shares represented by ADSs. The Deposit Agreement empowers the Depositary to vote Shares it holds pursuant to instructions received from ADS holders. The Deposit Agreement contains a provision facilitating conversion of ADSs to ordinary shares upon payment of a $5 per 100 share conversion fee.

 

·On October 17, 2022 the Company announced that it would delist from the London Stock Exchange.

 

·On December 13, 2022, the Company’s voluntary delisting from the London Stock Exchange became effective and trading of ordinary shares through that exchange ceased.

 

·Subsequently, over 90% of the Company’s Shares have come to be held through ADS arrangements and traded via Nasdaq rather than held directly by investors as ordinary shares.

 

·From October 2020 through early 2023 the Company experienced sustained financial underperformance and value destruction for Shareholders following the Nasdaq listing.

 

·During that time the public trading price of the Company’s stock fell from ~$19 per Share to a low of ~$13 per Share – a loss of about one-third of its market value in just over two years. This erosion of share value is out of step with the performance of peer companies, which enjoyed an average ~one-third increase in value during that same time, in a range of ~10% gain to a high of ~70% gain.

 

·During that time Abcam’s Return on Invested Capital (“ROIC”) dropped as well. Prior to Dr. Milner’s resignation, Abcam’s ROIC typically exceeded its Weighted Average Cost of Capital.

 

·On March 10, 2023 Dr. Milner filed an SEC Form 13G disclosing his direct beneficial ownership of 11,993,853 shares.

 

3

 

 

·On April 28, 2023, Dr. Milner met with Peter Allen, the Chairman of the Board, and Alan Hirzel, the Chief Executive Officer, to discuss the Company’s poor performance and the possibility that the Board would appoint him as a Director so he could help return the Company to strong performance.

 

·On May 1, 2023 Dr. Milner filed a Schedule 13D declaring “that he intends to become more actively involved in the affairs of the Issuer and to engage with the Issuer regarding its governance, performance and direction.”

 

·Given the Board’s disappointing response to his proposed return to the Board, and the Board’s discretion to call an extraordinary general meeting, and his 6.4% ownership of the Company, Dr. Milner reached out to the Depositary, through which he could vote the ordinary shares represented by his ADSs, to inquire about proper paths by which he could call an extraordinary general meeting regarding his proposed appointment to the Board that would not require that he first convert his ADSs into ordinary shares.

 

·On May 9, 2023, the Depositary, by its legal counsel, wrote to Dr. Milner’s legal counsel acknowledging the substantial fee required for conversion of ADSs to Ordinary Shares, and proposing a process which the Depositary thought was an alternative to call a general meeting without conversion of ADSs that should be fully acceptable to Abcam.

 

·On May 11, 2023, Dr. Milner addressed the Company through a letter from his legal counsel to ask that the Board exercise its discretion to call an extraordinary general meeting of the Shareholders if he should request such a meeting, or at a minimum, that the Company would permit him to direct the calling of such a meeting himself without having first to convert his ADS holdings into ordinary shares of the Company, following the procedures recommended by the Company’s own Depositary.

 

·On May 15, 2023, the Company responded through its legal counsel that the Board would not call an extraordinary general meeting at Dr. Milner’s request, claiming “we think it’s highly premature to explore the mechanics of requisitioning an Extraordinary General Meeting of the company’s shareholders.”

 

·On May 16, 2023, Dr. Milner replied through a letter by his legal counsel stating that the Company “is playing games and is not considering in good faith Dr. Milner’s candidacy for the Board” and it posed a question: “[w]e ask again – will the Company call an EGM if asked by Dr. Milner if that request is accompanied by evidence of his ownership of ADRs?”

 

·On May 17, 2023, a representative of the Company contacted Dr. Milner to advise him that the Board could agree to appoint him as a non-executive director if he would agree to certain restrictions on his rights as a shareholder and director, including standstill and non-disparagement agreements.

 

·The foregoing exchange of correspondence and other dealings with the Company convinced Dr. Milner that the Board would not work with him in good faith to join as a full member or to have an effective say in Company management thereafter, so he would instead need to obtain the authority needed to make required changes at the Company by action of its Shareholders instead. Factors leading to that conclusion included the Board’s use of ADRs to stifle shareholder franchise rights.

 

·On May 19, 2023, Dr. Milner initiated the conversion of 11.7 million ADSs to ordinary shares, and he paid the conversion fee of nearly $600,000 which was required by the conversion according to the Deposit Agreement.

 

·On May 30, 2023, Dr. Milner filed an amendment to his Schedule 13D which disclosed his delivery of a demand for a general meeting of the Company to be held to effect changes to the Board and a press release regarding that action.

 

·On May 30, 2023, Dr. Milner received word that the conversion of his ADSs to ordinary shares was completed.

 

4

 

 

·On June 5, 2023, Dr. Milner filed an amendment to his Schedule 13D which disclosed his publication of a Proxy Statement of Jonathan Milner dated June 5, 2023 in connection with his demand for the aforementioned general meeting.

 

·On June 6, 2023, Dr. Milner filed an amendment to his Schedule 13D which disclosed his publication of a slide-deck presentation regarding the Company entitled “Abcam in Focus.”

 

·On June 12, 2023, Dr. Milner filed an amendment to his Schedule 13D which disclosed his publication of a slide-deck presentation regarding the Company entitled “Abcam in Focus” and an open letter to Shareholders.

 

·On June 20, 2023, Dr. Milner filed an amendment to his Schedule 13D which disclosed his delivery of the June 19, 2023 letters to the Company and its legal counsel in connection with the aforementioned general meeting demand.

 

·On June 23, 2023, the Company announced that it had decided to initiate a process to explore strategic alternatives for the Company to maximize shareholder value, including a potential sale of the Company.

 

·On June 26, 2023, Dr. Milner announced the suspension of his solicitation to allow the Board to focus on pursuing its strategic review and thereby create maximum shareholder value.

 

·On August 16, 2023, Dr. Milner filed an amendment to his Schedule 13D which disclosed his publication of an open letter to the Board, publicly requesting an update by the Company with regard to its exploration of strategic alternatives for the maximization of value for shareholders.

 

·On August 28, 2023, the Company announced that it had entered into a definitive agreement pursuant to which Danaher would acquire all of the outstanding shares of Abcam for $24.00 per share in cash and that such transaction had been unanimously approved and recommended by the Board.

 

·On September 14, 2023, Dr. Milner announced his decision to oppose the Proposed Transaction on the basis that the $24.00 per share price substantially undervalues the Company and filed an amendment to his Schedule 13D in connection therewith.

 

·On September 18, 2023, Dr. Milner, through his legal counsel, sent a letter to Abcam (marked for the attention of Marc Perkins, Abcam’s Secretary and General Counsel) containing a request of shareholder records. That letter requested, among other things:

 

oDepository Trust Company list;

 

oAll information in, or which comes into, the possession of the Company, its transfer agent, its proxy solicitor, or any other of the Company’s agents or representatives, or which reasonably can be obtained from nominees of any central certificate depositary system as of the Determination Dates, concerning the number and identity of actual beneficial owners of the Company’s ordinary shares, including, without limitation: (i) a breakdown of any such holdings in the name of The Depository Trust Company - Cede & Co. (“Cede & Co.”) and any other similar securities depository or nominees; (ii) all omnibus proxies and all "Weekly Security Position Listing Daily Closing Balances" reports issued by Cede & Co, in or which comes into the possession of the Company, its transfer agent, its proxy solicitor, or any other of the Company’s agents or representatives, and if such information is not in the Company’s possession, custody or control, such information should be requested, obtained and provided to us;

 

oDTC Omnibus Proxy;

 

oRegistered American Depositary Receipts list: A complete record or list of the holders of the Company’s American Depository Shares, certified by the Company or its transfer agent, showing the name, address and number of shares registered in the name of each such holder;

 

5

 

 

oNon-Objecting Beneficial Owners list: All information as of the Determination Dates in or which comes into the possession of the Company, its transfer agent, its proxy solicitor, or any other of the Company’s agents or representatives, or which can reasonably be obtained from brokers, dealers, banks, clearing agencies or voting trustees relating to the names of the non-objecting beneficial owners (“NOBOs”) and consenting beneficial owners of the ordinary shares, including the name, address and the number of shares held by each NOBO. Such information is readily available to the Company under Rule 14b-1(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), from Broadridge Financial Solutions, Mediant Communications LLC, Say Technologies and other such entities and custodian banks;

 

oRespondent Bank Lists and Omnibus Proxies: All omnibus proxies and related respondent bank lists and omnibus proxies for such lists pursuant to Rule 14b-2 under the Exchange Act, as of the Determination Dates, in or which comes into the possession of the Company, its transfer agent, its proxy solicitor, or any other of the Company’s agents or representatives, issued by Broadridge Financial Solutions, Inc., Mediant Communications LLC, Say Technologies, and other such entities;

 

oElectronic Mail Addresses: To the extent the Company, or any person or entity acting at its behest, or on its behalf, maintains or begins to maintain electronic mail addresses or other electronic contact information concerning shareholders for the purpose of communicating with such shareholders, all such information as of the Determination Dates; and

 

oMaterial Request Lists: Any material request lists as of the Determination Dates in or which comes into the possession of the Company, its transfer agent, its proxy solicitor, or any other of the Company’s agents or representatives, provided by Broadridge Financial Solutions, Inc., Mediant Communications LLC, Say Technologies, and other such entities.

 

·On September 25, 2023, Abcam sent a letter to Dr. Milner’s legal counsel indicating Abcam’s refusal to provide the records noted above. That letter stated, in part:

 

We note that your Request asks the Company to provide copies of certain other records relating to the legal and beneficial ownership of American depositary shares, in addition to the Registers. As you may be aware, sections 116 and 811 of the Companies Act 2006 only require the Company to provide, on receipt of a valid request, copies of specific statutory registers. The Company will not therefore be providing you with copies of the broader records listed in your Request, which are beyond the scope of these provisions of the Companies Act 2006.

 

6

 

 

REASONS FOR THE SOLICITATION

 

·Dr. Milner believes that the Proposed Transaction grossly undervalues Abcam.

 

·Dr. Milner believes that the $24 per share price fails to provide any meaningful bid premium to the owners of an outstanding UK life sciences asset.

 

·The Board’s acceptance of the terms of the Proposed Transaction within such a short period of time (approximately two months) after announcing a review of strategic alternatives, including a potential sale, appears to indicate a rushed process.

 

·Dr. Milner understands that the Company has put in place excessively favourable arrangements for management in connection with a sale of the Company, which creates a perverse incentive for the Board to recommend the Proposed Transaction.

 

·Following Dr. Milner initiating a campaign to be appointed as Executive Chairman of the Board on or around May 2023, the Company’s share price experienced a notable increase, surging from approximately $15 to approximately $22 per share, a 47% increase in value. Dr. Milner believes that the shares in the Company should be trading at these levels if the Company were under the stewardship of a competent and disciplined management and Board with a clear strategy to further drive shareholder value going forwards.

 

·If the requisite shareholder approvals (as described in more detail later in this Proxy Statement) are not forthcoming in respect of the Proposed Transaction, Dr. Milner intends to requisition a general meeting of the Company with the object of reshaping the Board, including the removal of the current CEO, CFO and Chairman from office.

 

·Further details of Dr. Milner’s reasons for the solicitation and his strategic proposals for the Company are set forth in his open letter to the Shareholders dated the date of this Proxy Statement and on the website www.abcamfocus.com.

 

7

 

 

Dr. Milner

 

Dr. Milner is pursuing this solicitation of proxies from Shareholders (including ADS Holders). His principal business address is Honey Hill House, 20 Honey Hill, Cambridge, CB3 0BG, United Kingdom.

 

Annex A sets forth all transactions in securities of Abcam he has effected during the past two years and his total beneficial ownership of securities of Abcam.

 

Dr. Milner intends to vote all Shares under his beneficial ownership AGAINST the Proposed Transaction. As set forth more fully under Annex A, Dr. Milner may be deemed to beneficially own, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), 14,156,202 Shares, representing approximately 6.15% of outstanding Shares, based upon the 230,148,147 Shares outstanding as of August 31, 2023, as disclosed in the Form SH01 filed at the Companies House of the United Kingdom on September 21, 2023. Dr. Milner is a trustee and signatory over shares held by a charitable trust, exercises investment discretion over and has authority to vote Shares beneficially owned by three certain limited liability companies. Dr. Milner disclaims beneficial ownership of Shares owned by his spouse except to the extent of his pecuniary interest in those Shares.

 

Dr. Milner is independent from the Company under the independence standards applicable to the Company under paragraph (a)(1) of Item 407 of Regulation S-K.

 

Except as set forth herein, (a) Dr. Milner is not, and was not within the past year, a party to any contract, arrangement or understanding with any person with respect to any securities of Abcam, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies; (b) Dr. Milner, and no associate of Dr. Milner, to his knowledge, has any arrangement or understanding with any person with respect to (x) any future employment by Abcam or its affiliates or (y) any future transactions to which Abcam or any of its affiliates will or may be a party; (c) Dr. Milner, and no associate of Dr. Milner, owns beneficially, directly or indirectly, any securities of Abcam or any subsidiary of Abcam; and (d) Dr. Milner, and no associate of Dr. Milner, to his knowledge, was a party to a transaction that is required to be described under Item 404(a) of Regulation S-K.

 

Except as set forth herein, (a) neither Dr. Milner, nor any associate of him, is a party adverse to Abcam or any of its subsidiaries or has a material interest adverse to Abcam or any of its subsidiaries in any material proceeding; (b) there is no event that occurred during the past 10 years with respect to him that is required to be described under Item 401(f) of Regulation S-K; and (c) there is no arrangement or understanding between him and any other person pursuant to which they are to be selected as a nominee hereunder.

 

Scheme Circular

 

Dr. Milner makes no representation, warranty, assurance or undertaking (express or implied) with respect to the content of the Scheme Circular and accepts no responsibility for the content thereof. All and any such responsibility and liability is expressly disclaimed to the fullest extent permitted by applicable law.

 

Forward-Looking Statements

 

This Proxy Statement contains forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “potential,” “could,” “opportunity,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. The statements contained herein that are not historical facts are based on current expectations, speak only as of the date of this Proxy Statement and involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by such statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Dr. Milner. Although Dr. Milner believes that the assumptions underlying the forward-looking statements are reasonable as of the date of this Proxy Statement, any of the assumptions could be inaccurate and therefore, there can be no assurance that the forward-looking statements included herein will prove to be accurate and therefore actual results could differ materially from those set forth in, contemplated by, or underlying those forward-looking statements. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation as to future results or that the objectives and strategic initiatives expressed or implied by such forward-looking statements will be achieved. Except to the extent required by applicable law, Dr. Milner will not undertake and specifically declines any obligation to disclose the results of any revisions that may be made to any forward-looking statements herein to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

8

 

 

HOW TO VOTE

 

Generally

 

According to applicable law, the relevant courts in England and Wales may approve the Proposed Transaction if a majority in number representing 75% in value of the eligible members or class of members, present and voting either in person or by proxy at the Court Meeting, approve the Proposed Transaction. Further details in respect of the threshold requirements are set forth below. Abstentions and broker non-votes will have no effect on the vote outcome. As a result, your vote is extremely important. We urge Shareholders (including ADS Holders) to vote AGAINST the Proposed Transaction on the WHITE proxy card.

 

If you attend the Court Meeting in person and you beneficially own Shares but are not the record owner, including if your Shares are represented by ADSs, your mere attendance at the Court Meeting WILL NOT be sufficient to vote your Shares or to cancel your prior given proxy card.

 

YOUR FAILURE TO ACT ACCORDING TO PROPER VOTING PROCEDURE COULD NEGATE YOUR INTENDED VOTE. IF YOU HAVE ANY QUESTIONS ABOUT THE VOTING PROCESS OR REQUIRE ANY OTHER ASSISTANCE WITH EXECUTING YOUR PROXY AND VOTING, PLEASE CONTACT:

 

Alliance Advisors LLC

200 Broadacres Drive, 3rd Floor

Bloomfield, New Jersey 07003

Shareholders in North America call: 877-777-8211

Shareholders outside North America call: 0800-102- 6998

By Email: focusabcam@allianceadvisors.com

 

This Proxy Statement, as well as other proxy materials distributed by or for Dr. Milner regarding the Court Meeting, will be available free of charge online at www.abcamfocus.com.

 

Only holders of record of Shares as of the close of business on a record date and time to be announced by the Company (the “Company Record Date”) will be entitled to notice of, and to attend and to vote at, the Court Meeting and any adjournments, postponements or continuations thereof. We expect the Company will disclose the number of Shares issued and outstanding as of the Company Record Date at or about the time it announces the Company Record Date and the Court Meeting date.

 

Once the Company has fixed the Company Record Date, the Depositary shall, pursuant to the Depositary Agreement1, fix a record date for the determination of the ADS Holders who shall be entitled to give instructions for the exercise of voting rights at the Court Meeting (the “ADS Record Date”). The Depositary must make reasonable efforts to establish the ADS Record Date as closely as practicable to the Company Record Date. Only holders of record of ADSs as of close of business in New York on the ADS Record Date shall be entitled to give instructions to the Depositary to vote their underlying Scheme Shares (as defined below) at the Court Meeting.

 

The Company Record Date and the ADS Record Date will be posted online at www.abcamfocus.com promptly after the Company or the Depositary (as applicable) announces it. You are encouraged to check www.abcamfocus.com frequently for updates.

 

 

1 §§4.9 and 4.10 of the Deposit Agreement

 

9

 

 

Quorum; Voting Procedures

 

Abcam is registered in England & Wales and is therefore subject to the Companies Act, which, together with the articles of association of Abcam (the “Articles”), governs the processes for shareholder voting at Shareholder meetings. There are a number of differences between English and U.S. law in relation to voting. Given the shareholder approval requirements under the Companies Act in connection with the Proposed Transaction, as further detailed below, the resolution put to the vote of the Court Meeting will be by way of a poll.

 

Only holders of record of the Shares at the close of business on the Company Record Date, shall be entitled to notice of, and to attend and to vote at, the Court Meeting. A large percentage of the Company’s Shares are and on the Company Record Date will be held in the name of the Depositary which issues Company-sponsored ADSs which, in turn, each represent one Share.

 

Persons who own Shares indirectly on the ADS Record Date through a brokerage firm, bank or other financial institution, including persons who own Shares in the form of ADSs through the Depositary, must return a voting instruction form to have their Shares or the Shares underlying their ADSs, as the case may be, voted on their behalf.

 

Under U.S. national securities exchange rules, if such person does not provide voting instructions, their brokerage firm, bank or other financial institution is only allowed to vote their securities on routine matters and cannot vote their securities on any non-routine matter. A “broker non-vote” occurs when a brokerage firm, bank, or other financial institution holding the securities for a beneficial owner votes on one proposal but does not vote on another proposal because, with respect to such other proposal, the brokerage firm, bank or financial institution does not have discretionary voting power and has not received instructions from the beneficial owner as to how to vote such securities. We are not aware of any routine matters being presented at the Court Meeting. For non-routine matters, brokers, or other nominees, do not have authority, discretionary or otherwise, to vote the securities of a beneficial owner unless they receive proper instructions to do so from the beneficial owner in a timely manner.

 

We encourage you to provide voting instructions to your brokerage firm, bank or other financial institution by giving your proxy to them as promptly as possible to ensure that your Shares will be voted at the Court Meeting according to your instructions. You should receive directions from your brokerage firm, bank or other financial institution about how to submit your proxy to them at the time you receive this Proxy Statement. Instructions regarding how to vote and how to submit your vote will be provided on each proxy card and voting instruction form you will receive, and you are encouraged to follow those instructions carefully and submit your vote in a timely manner. If you have any questions about completion or submission of the form, contact Alliance Advisors utilizing the contact information provided in this Proxy Statement.

 

At the Court Meeting, broker non-votes will not be counted for the purpose of determining the number of votes cast on a given proposal. The required vote for each of the proposals expected to be acted upon at the Court Meeting is described below.

 

Vote Required for Approval

 

According to applicable law, the relevant courts in England and Wales may approve the Proposed Transaction if a majority in number of the shareholders who are on the register of members of the Company on the Company Record Date and who are present and vote, whether in person or by proxy, at the Court Meeting and who represent not less than 75% in value of the Scheme Shares voted by those shareholders, approve the Proposed Transaction.

 

“Scheme Shares” are ordinary shares of the Company (a) in issue as at the date of the Scheme Circular, (b) issued after the date of the Scheme Circular but before the Company Record Date, and (c) issued after the Company Record Date but before the “Scheme Record Date” (being the date and time to be specified in the Scheme Circular by reference to which the shares transferring to Danaher under the Proposed Transaction shall be determined) in respect of which the original or any subsequent holder thereof is bound by the scheme of arrangement relating to the Proposed Transaction. Scheme Shares do not include ordinary shares held by Danaher or its nominees or held by the Company in treasury.

 

Both the Company Record Date and the Scheme Record Date should be specified in the Scheme Circular and will be posted online at www.abcamfocus.com promptly after the Company announces them. You are encouraged to check www.abcamfocus.com frequently for updates.

 

10

 

 

HOW TO VOTE

 

ADS Holders

 

There are two ways ADS Holders as of the ADS Record Date may vote. Such Persons may:

 

1. Mark, sign, date and lodge the enclosed WHITE Proxy Card (together with a duly signed and dated power of attorney or other authority (if any) under which it is executed (or a notarized copy of such power of attorney or other authority)), by returning the Proxy Card to the Depositary or your relevant bank, broker or other nominee (as applicable), in each case, in accordance with their instructions, so as to be received by a date and time to be announced by the Depositary, which date is expected to be approximately a week before the Court Meeting (the “ADS Instruction Date”) – each proxy properly tendered will, unless otherwise directed by the ADS Holder, be voted AGAINST the Proposed Transaction at the Court Meeting; or  

 

2. ADS Holders are entitled to vote their ADSs (and underlying Shares) in accordance with any separate instructions that the Depositary or their relevant bank, broker or other nominee (as applicable) may send. However, Dr. Milner encourages all ADS Holders to vote AGAINST the Proposed Transaction on the WHITE proxy card so that an accurate assessment of votes can be made.  

 

You are urged to complete the enclosed WHITE Proxy Card and lodge it return it to the Depositary or your relevant bank, broker or other nominee (as applicable) in accordance with their instructions so as to be received by no later than the ADS Instruction Date. If you specify a choice with respect to the proposal by marking the appropriate box on the proxy, the ADSs will be voted in accordance with that specification. IF NO SPECIFICATION IS MADE IN RESPECT OF THE PROPOSED TRANSACTION, ALL ADSS REPRESENTED BY THE PROXY WILL BE VOTED AGAINST THE PROPOSED TRANSACTION.

 

ADS holders are not entitled to vote directly at the Court Meeting, but a Deposit Agreement dated as of October 26, 2020 (the “Deposit Agreement”), exists among the Company, the Depositary and all holders and beneficial owners of ADSs issued thereunder pursuant to which registered holders of ADSs as of the ADS Record Date are entitled to instruct the Depositary as to the exercise of voting rights pertaining to the Shares so represented. The Depositary has agreed that it will endeavor, insofar as practicable, to vote (in person (if permitted) or by delivery to the Company of a proxy) the Shares registered in the name of the Depositary, in accordance with the instructions of the ADS holders. In the event that the Depositary timely receives voting instructions from an ADS holder which fail to specify the manner in which the Depositary is to vote the Shares represented by such holder’s ADSs, the Depositary will deem such ADS holder (unless otherwise specified in the notice distributed to ADS holders) to have instructed the Depositary to vote in favor of the items set forth in such voting instructions. Instructions from ADS holders must be sent to the Depositary so that the instructions are received by a date and time to be announced by the Depositary, which date is expected to be approximately a week before the Court Meeting. Shares represented by the ADSs for which ADS holders have not timely submitted valid voting instructions to the Depositary shall not be voted unless exceptions apply pursuant to §4.10 of the Deposit Agreement.

 

Persons who own Shares indirectly on the ADS Record Date through a bank, broker or other nominee, must return a voting instruction form to such bank, broker or other nominee to have their Shares voted on their behalf. We encourage you to provide voting instructions to your bank, broker or other nominee by giving your proxy to them as promptly as possible to ensure that your Shares will be voted at the Court Meeting according to your instructions.

 

You should receive a WHITE voting instruction form from your bank, broker or other nominee about how to submit your voting instructions to them at the time you receive this Proxy Statement.

 

11

 

 

Direct Shareholders

 

There are three ways persons who hold Shares registered in their own name on the Company Record Date may vote. Such Persons may:

 

1.  Mark, sign, date and lodge the enclosed WHITE Proxy Card (together with a duly signed and dated power of attorney or other authority (if any) under which it is executed (or a notarized copy of such power of attorney or other authority)), by delivering the proxy either by hand or by post, at the offices of Alliance Advisors, 205a High Street, West Wickham, Kent, United Kingdom, BR4 0PH, so as to be received by a date and time to be announced by the Company, which date is expected to be approximately two days before the Court Meeting (the “Ordinary Share Instruction Date”) – each proxy properly tendered will, unless otherwise directed by the Shareholder, be voted AGAINST the Proposed Transaction at the Court Meeting;

 

2. Vote in person by submitting a written ballot in person at the Court Meeting; or

 

3.  Shareholders are entitled to execute and return a proxy card the Company may send.  However, Dr. Milner encourages all Shareholders to vote in favor of the proposals on the WHITE proxy card so that so that an accurate assessment of votes can be made.

 

The Articles provide that Persons who own Shares who desire to attend a general meeting must have their names entered on the Register at a time specified in the notice of meeting, but which is not more than 48 hours before the time fixed for the meeting.2

 

Regardless of whether you are able to attend the Court Meeting, you are urged to complete the enclosed WHITE Proxy Card and lodge it at the office of Alliance noted above so as to be received by no later than the Ordinary Share Instruction Date. All valid proxies received prior to the meeting will be voted. If you specify a choice with respect to the proposal by marking the appropriate box on the proxy, the Shares will be voted in accordance with that specification. IF NO SPECIFICATION IS MADE, ALL SHARES REPRESENTED BY THE PROXY WILL BE VOTED AGAINST THE PROPOSED TRANSACTION.

 

Proxy Procedures

 

IN ORDER FOR SHAREHOLDERS (INCLUDING ADS HOLDERS) TO VOTE AS RECOMMENDED IN THIS PROXY STATEMENT, PLEASE MARK, SIGN AND DATE THE ENCLOSED WHITE PROXY CARD AND RETURN IT IN ACCORDANCE WITH THE INSTRUCTIONS NOTED ABOVE.

 

IF YOU ARE UNCLEAR ABOUT THE SUBMISSION DEADLINE OR THE SUBMISSION PROCEDURE OR ANY OTHER ASPECT OF THE VOTING PROCESS, PLEASE CONTACT ALLIANCE ADVISERS FOR ASSISTANCE UTILIZING THE CONTACT INFORMATION PROVIDED ABOVE.

 

Only ADS Holders as of the ADS Record Date, and Shareholders as of the Company Record Date, will be entitled to vote. If you were an ADS Holder on the ADS Record Date or a Shareholder on the Company Record Date, you will retain your voting rights even if you sell such ADSs after the ADS Record Date or you sell such Shares after the Company Record Date (as applicable). Accordingly, it is important that you vote the ADSs held by you on the ADS Record Date and you vote the Shares held by you on the Company Record Date, or grant a proxy to vote such ADSs or Shares, even if you sell such ADSs after the ADS Record Date or you sell such Shares after the Company Record Date (as applicable).

 

 

2 Articles Section 58.3

 

12

 

 

Revocation of Proxies

 

Indirect shareholders, including ADS Holders

 

ADS Holders who have voted using the enclosed WHITE proxy card may revoke or change their proxy instructions up to 48 hours prior to the vote at the Court Meeting by submitting to the Depositary or your relevant bank, broker or nominee (as applicable) a properly executed, subsequently dated, and lodged proxy card that will revoke all prior voting instructions or proxy cards, including any proxy cards that you may have submitted to Abcam, the Depositary, or your relevant bank, broker or nominee (as applicable).

 

Although such a revocation is effective if delivered in accordance with the above instructions, Dr. Milner requests that either the original or a copy of any revocation be mailed to him c/o Alliance Advisors, 205a High Street, West Wickham, Kent, United Kingdom, BR4 0PH, United Kingdom so that he will be aware of all revocations.

 

Persons who hold Shares represented by ADSs or held by a bank, broker or other nominee and who otherwise wish to change or revoke their voting instructions should also contact such intermediary for information on how to do so. ADS Holders are strongly encouraged to submit their voting instructions as soon as possible. Keep in mind that only your last-dated instructions will be considered in the vote tabulations.

 

Direct Shareholders

 

Persons who hold Shares directly may revoke or change their proxy instructions up to 48 hours prior to the vote at the Court Meeting by:

 

·submitting a properly executed, subsequently dated, and lodged proxy card that will revoke all prior voting instructions or proxy cards, including any proxy cards that you may have submitted to Abcam; or

 

·attending the Court Meeting and withdrawing your proxy by voting in person (although attendance at the Court Meeting will not in and of itself constitute revocation of a proxy).

 

Although such a revocation is effective if delivered in accordance with the above instructions, Dr. Milner requests that either the original or a copy of any revocation be mailed to him c/o Alliance Advisors, 205a High Street, West Wickham, Kent, United Kingdom, BR4 0PH, United Kingdom so that he will be aware of all revocations.

 

Delivery of Proxy Materials

 

Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of this Proxy Statement may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of the document to you if you call or write to Alliance Advisors LLC, at the address set forth above on the back cover of this Proxy Statement.

 

Cost and Method of Solicitation

 

Dr. Milner has retained Alliance Advisors to conduct solicitation on his behalf, for which Alliance Advisors is to receive a fee of up to $150,000. Dr. Milner has agreed to indemnify Alliance Advisors against certain liabilities and expenses. Proxies may be solicited by mail, courier services, Internet, advertising, telephone, telecopier, or in person. It is anticipated that Alliance Advisors will employ up to 25 persons to solicit proxies from ADS Holders for the Court Meeting. The total expenditures in furtherance of, or in connection with, the solicitation of proxies is approximately $1,000,000 to date, and is estimated to be approximately $2,500,000 in total. Dr. Milner will bear all costs associated with this solicitation as necessary.

 

13

 

 

Additional Information

 

Certain information relating to Abcam is not included in this Proxy Statement. Such information includes interests of certain persons in matters to be acted upon at the Court Meeting, the securities of Abcam held by Abcam’s directors, executive officers and 5% shareholders, information regarding the directors and management of Abcam, and the date by which proposals of security holders intended to be presented at the next annual general meeting of Shareholders must be received by Abcam. We expect such information will be provided by or otherwise made available by the Company, and Dr. Milner takes no responsibility for the accuracy or completeness of any information contained in or taken from Abcam’s public filings or otherwise provided by Abcam.

 

Date: September 28, 2023

 

  /s/ Jonathan Milner
  Jonathan Milner

 

14

 

 

ANNEX A

 

Dr. Milner’s Beneficial Ownership of Company Securities

 

As of the date of publication of this Proxy Statement, Dr. Milner may be deemed to beneficially own, within the meaning of Rule 13d-3 under the Exchange Act, 14,156,202 Shares, representing approximately 6.15% of outstanding Shares. Percentages of outstanding Shares stated here are based upon the 230,148,147 Shares outstanding as of August 31, 2023, as disclosed in the Form SH01 filed at the Companies House of the United Kingdom on September 21, 2023. Dr. Milner personally holds 11,700,200 Ordinary Shares and 45,200 ADSs. Dr. Milner is a trustee and signatory over 33,453 ADSs held by a charitable trust, exercises investment discretion over and has authority to vote the 1,977,967 ADSs beneficially owned by three certain limited liability companies. Dr. Milner disclaims beneficial ownership over the 339,382 ADSs owned by his spouse except to the extent of his pecuniary interest in those Shares.

 

Summary Table

 

The following table indicates the date of each purchase and sale of securities of the Company of Dr. Milner within the past two years and the number of securities in each such transaction. No part of the purchase price or market value of the securities listed below is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities.

 

Name Date Purchased/(Sold)
Dr. Jonathan Milner 5-Nov-21 (112,210)
Dr. Jonathan Milner 9-Dec-21 (133,178)
Dr. Jonathan Milner 24-Dec-21 (16)
Dr. Jonathan Milner 29-Dec-21 (9,372)
Dr. Jonathan Milner 30-Dec-21 (170,000)
Dr. Jonathan Milner 30-Dec-21 (146,451)
Dr. Jonathan Milner 11-Jan-22 (1)
Dr. Jonathan Milner 23-Sep-22 (94,769)
Dr. Jonathan Milner 14-Oct-22 (9,333)*
Dr. Jonathan Milner 14-Oct-22 (9,333)*
Dr. Jonathan Milner 14-Oct-22 (9,333)*
Dr. Jonathan Milner 14-Oct-22 (12,000)*
Dr. Jonathan Milner 17-Oct-22 (14,000)*
Dr. Jonathan Milner 17-Oct-22 (1)*
Dr. Jonathan Milner 28-Oct-22 (14,000)*
Dr. Jonathan Milner 28-Oct-22 (14,000)*
Dr. Jonathan Milner 28-Oct-22 (12,000)*

 

15

 

 

Dr. Jonathan Milner 4-Nov-22 (11,000)*
Dr. Jonathan Milner 5-Dec-22 (14,000)*
Dr. Jonathan Milner 26-Jan-23 (9,901)
Dr. Jonathan Milner 26-Jan-23 (15,099)
Dr. Jonathan Milner 17-Apr-23 (65,000)
Dr. Jonathan Milner 19-Apr-23 (54,996)
Dr. Jonathan Milner 19-Apr-23 (10,004)
Dr. Jonathan Milner 20-Apr-23 (65,000)
Dr. Jonathan Milner 25-Apr-23 (65,000)
Dr. Jonathan Milner 29-June-2023 (33,453)**
Dr. Jonathan Milner 11-Sept-2023 4,500
Dr. Jonathan Milner 12-Sept-2023 4,500
Dr. Jonathan Milner 13-Sept-2023 4,500
Dr. Jonathan Milner 14-Sept-2023 4,500
Dr. Jonathan Milner 15-Sept-2023 4,500
Dr. Jonathan Milner 18-Sept-2023 4,500
Dr. Jonathan Milner 19-Sept-2023 4,500
Dr. Jonathan Milner 20-Sept-2023 4,500
Dr. Jonathan Milner 21-Sept-2023 4,500
Dr. Jonathan Milner 22-Sept-2023 4,500

 

*          Denotes a gift

**       Denotes transfer to charitable trust

 

16

 

 

IMPORTANT

 

Your vote is important, no matter how many Shares or ADSs you own.

 

We urge you to vote AGAINST the Proposed Transaction.

 

1. If your Shares are represented by ADSs, please mark, sign and date the enclosed WHITE Proxy Card and return it in accordance with the instructions you receive from the Depositary or your relevant bank, broker or nominee (as applicable) so as to be received by no later than the ADS Instruction Date.

 

2. If your Shares are registered in your own name, please mark, sign and date the enclosed WHITE Proxy Card and lodge it at Alliance Advisors, 205a High Street, West Wickham, Kent, United Kingdom, BR4 0PH so as to be received by no later than the Ordinary Share Instruction Date.  

 

If you have any questions or require any assistance in executing or delivering your proxy, please call:

 

Alliance Advisors LLC

200 Broadacres Drive, 3rd Floor

Bloomfield, New Jersey 07003

Shareholders in North America call: 877-777-8211

Shareholders outside North America call: 0800-102- 6998

By Email: focusabcam@allianceadvisors.com

 

17

 

 

**DR. MILNER RECOMMENDS THAT YOU TO VOTE AGAINST THE PROPOSED TRANSACTION**

 

WHITE PROXY CARD

 

ABCAM PLC

THIS PROXY IS SOLICITED ON BEHALF OF DR. JONATHAN MILNER

 

I/We:

(Enter name(s) in full block capital letters, please)

Of:

 

being (a) member of Abcam plc (the “Company”) hereby appoint each of Dr. Jonathan Milner, Richard Brand, Esq., Michael Newell, Esq. and Carlo Pia, Esq. to attend, speak, and vote for me/us and on my/our behalf as identified by an “X” in the appropriate box below at, and in their discretion on other matters that may properly come before, the meeting(s) of Shareholders convened with the permission of a court of competent jurisdiction in England and Wales under the United Kingdom Companies Act 2006 in connection with the proposed acquisition by Danaher Corporation (NYSE: DHR) or one of its affiliates of all of the outstanding shares of the Company for $24.00 per share to be effected by means of a court-approved scheme of arrangement pursuant to the United Kingdom Companies Act 2006, which is to be held at the Company’s offices at Discovery Drive, Cambridge Medical Campus, Cambridge, CB2 0AX, United Kingdom or another location to be announced by the Company, including any adjournments, postponements or continuations thereof.

 

I/We instruct my/our proxy to vote as follows:

 

 

Resolution

 For Against

Abstain

(see n.2)
THAT the scheme of arrangement to effect the acquisition by Danaher Corporation (or one of its affiliates) of shares in the Company at a price equal to $24.00 per share, such scheme of arrangement as more particularly described in a circular published or to be published by the Company (such scheme of arrangement in its original form or with or subject to any modification, addition or condition made thereto in accordance with applicable law) (the “Scheme”) and approved or imposed by a court of competent jurisdiction in England and Wales, be approved and the directors of the Company (or a duly authorised committee thereof) be authorised to take all such actions as they may consider necessary or appropriate for carrying the Scheme into effect.      

 

Dated: 

 

This proxy, when properly executed, will be voted in the manner directed therein. If no such direction is made, this proxy will be voted AGAINST the resolution.

 

18

 

 

Notes:

 

1.  Please indicate with an “X” in the appropriate box how you wish the proxy to vote. In the absence of any indication, this proxy will be voted AGAINST the resolution.

 

2.  If you mark the box “abstain”, it will mean that your proxy will abstain from voting and, accordingly, your vote will not be counted either for or against the resolution.

 

3.  The form of proxy should be signed and dated by the member or his attorney duly authorized in writing. If the appointer is a corporation this proxy should be under seal or under the hand of an officer or attorney duly authorized. Any alteration made to the form of proxy should be initialed.

 

4.  To be valid, this form of proxy, together with a duly signed and dated power of attorney or any other authority (if any) under which it is executed (or a notarized copy of such power of attorney or other authority) must be signed and dated and (i) if your Shares are represented by ADSs, returned to the Depositary or your relevant bank, broker or nominee (as applicable) in accordance with their instructions, so as to be received by a date and time to be announced by Citibank, N.A. as Depositary, which date is expected to be approximately one week before the Court Meeting; and (ii) if you hold your Shares directly, by delivering the proxy either by hand or by post to Alliance Advisors, 205a High Street, West Wickham, Kent, United Kingdom, BR4 0PH, so as to be received by them by a date and time to be announced by the Company, which date is expected to be approximately two days before the Court Meeting.
   
5. In the case of joint holders of Shares, signature of any one holder will be sufficient, but the names of all the joint holders should be stated.  The vote of the senior holder (according to the order in which the names stand in the register of members in respect of the holding) who tenders a vote in person or by proxy will be accepted to the exclusion of the vote(s) of the other joint holder(s).
   
6. Completion and return of a form of proxy will not preclude a direct holder of Shares from attending, speaking and voting at the meeting or any adjournment thereof in person.  If a proxy is appointed and the direct holder of Shares attends the meeting in person, the proxy appointment will automatically be terminated.

 

19

 

 

Exhibit 99.19

 

Jonathan Milner issues Open Letter to shareholders of Abcam plc

 

Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation

 

CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.15%, today issued an open letter to the Company’s shareholders announcing his “Vote AGAINST” campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE: DHR) or its affiliates (“Danaher”) and Abcam’s governance, execution and cost control.

 

Find out more and read the full text of the letter at the Focus Abcam website.

 

The full text of the letter follows:

 

“Dear Fellow Abcam Shareholders,

 

Time for change, calling for focus

 

In late 2022 and early 2023, my concerns as a shareholder in our company grew significantly regarding Abcam’s performance following my departure from the Board in October 2020. Subsequently, I initiated a series of consultations with other owners of the business. By April of this year, my efforts revealed what I believe to be a distressing series of issues, including inadequate governance, lacklustre investor relations, deficient cost controls, and subpar execution.

 

In light of these well-documented failures, which I have extensively detailed on my website, I found it imperative to take action. I sought to rejoin the Board with the intention of leveraging my experience and expertise to help steer Abcam back to its previous fortunes. Regrettably, my request to rejoin the Board was beset with restrictions that would have limited my ability to contribute meaningfully and would have impeded my fiduciary responsibilities. Consequently, I felt compelled to convene an Extraordinary General Meeting (EGM) where I advocated for the selective replacement of the CFO, Chairman, and Chair of the Remuneration Committee, all of whom I identified as the principal contributors to the Company’s misfortunes. My aim was to rejoin the Company, with the intent of collaborating effectively with the current CEO, Alan Hirzel, as I had done previously.

 

June – Review of strategic alternatives

 

In June 2023, the Board made a significant announcement, stating that the Company had initiated a process to explore strategic alternatives for the Company by evaluating a broad range of options to maximise shareholder value, including ‘a potential sale.’ I agreed at the time that the Board should be given the opportunity to conduct this process I hoped that such a process would have started by addressing some of the actions I had spelt out in my June letter to shareholders, but I have also always openly supported a sale of the Company at a full and fair price. Therefore, reluctantly, I decided to withdraw my EGM resolutions to provide the Company with the necessary time and space to conduct the review and identify the best path forward for all shareholders. However, given the historical disregard and lack of consideration for shareholders displayed by the Executive Directors and the Board, I held reservations about the outcome of this review. I made it clear at the time in a public statement that I would review progress in the Autumn and that if it seemed that a full and fair process had not been run, I would reinstate my call for an EGM and hold the Board accountable. I also offered to rejoin the Board in any capacity (subject to a customary non-executive director contract but with no discriminatory restrictions that would prevent me from performing my duties) to bring my experience, expertise, and shareholder perspective to help with the strategic review process. This offer was not acted upon.

 

 

 

 

August – $24: the wrong price at the wrong time

 

My concerns were validated on August 28th when the Company disclosed that it had received what I, and other shareholders, consider to be an inadequately low offer of $24 per share from Danaher. I believe that this offer grossly undervalues Abcam, confirming my doubts about the Board’s commitment to securing the best deal for shareholders. This derisory offer highlights the gulf that has developed between the Board and shareholders. I believe the Company’s review of strategic alternatives had only one outcome in mind, namely, a sale of the business to deflect attention away from my call for focus on key metrics, governance and Executive Directors’ performance. I believe the proposals I have outlined for Abcam would provide a far better outcome for shareholders, returning the Company to the position it previously held as a premium-rated life sciences company with a long track record of impeccable execution and an absolute focus on shareholder value.

 

When I initiated my campaign earlier this year, my focus on fixing Abcam resonated with institutional investors and the share price experienced a notable increase, surging from approximately $15 to around $22, a 47% increase in value. Whilst some of this increase in value can be attributed to the mere action of initiating a review of strategic alternatives, it is my belief that the stock should be trading at these levels if the Company were under the stewardship of competent and disciplined executives and a Board with a clear strategy to further drive shareholder value going forwards.

 

The Executive Directors have argued that I should have waited for the shareholder circular to be published to understand the details of the negotiation process. I believe a detailed explanation of the negotiation process misses the point and will only serve to incur more costs and waste more time. With the strategic review being launched at a time when the Company’s performance was not optimal and sector multiples depressed, I believe it was highly unlikely to deliver full value for shareholders against that backdrop. Couple this with the swift acceptance of what I believe to be a subpar bid (within a mere two-month timeframe) and excessively favourable financial arrangements for Executive Directors (which I believe presents a significant conflict of interest), all at the expense of shareholders, and you reach what I maintain is the derisory offer of $24 per share that the Board wishes to recommend to you. Put simply, I believe $24 per share is the wrong price at the wrong time for a company that is a globally recognised brand in the life sciences sector.

 

Next steps – Vote AGAINST and consider my alternative plan for value creation at a forthcoming EGM

 

I believe that $24 per share is the wrong price at the wrong time for all of the reasons stated above. It seems nonsensical to be rushed into accepting $24 per share now when the deal is not expected to close until June 2024 at the earliest and there is a real opportunity to restore Abcam to a high performing and highly valued business that is recognised for its quality the world over. Like all shareholders, I believe there is a full and fair price to acquire control of Abcam and I shall not stand in the way of such an offer. However, I also maintain that without a strategic premium being paid now is not the right time to sell the business and, under my stewardship, we can turn around Abcam's fortunes.

 

Vote AGAINST to take the first step in seeing real shareholder value creation. Upon the successful conclusion of the “Vote AGAINST” campaign and the subsequent withdrawal of the proposed deal, my immediate course of action will involve calling for an EGM with the objective of reshaping the Company's Board, including the removal of the current CEO, CFO, and Chairman. I have created a shadow Board for Abcam, composed of highly qualified and independent nominees who share my vision. These individuals bring substantial sector expertise and adhere to top-tier governance practices and would be led by an experienced, industry-proven Chair to provide oversight and ensure accountability for the entire Board, myself included. I would assume the role of full-time CEO and one of my first tasks would be to reach out to the highly talented and dedicated staff at Abcam and provide leadership, focus and empathy with what will have been a long period of uncertainty.

 

 

 

 

Having served Abcam as CEO from 1999 to 2014 and later as Deputy Chairman from 2015 to 2020, I would bring a depth of insight into the Company and my tenure has consistently demonstrated excellent investor relations and a commitment to delivering shareholder value. Building on this legacy, earlier this year, I rolled out a six-month plan, aimed at elevating Abcam's market position by refocusing on the Group’s core leadership position in antibodies, improving operating and EBITDA margins, boosting free cash flow, and resuming dividend payments. This will include continuing the strategy that I initiated when I was CEO and supported as Deputy Chairman of increasing in-house manufacturing of Abcam’s own high-quality, high-margin products and decreasing reliance on third-party reagents.

 

Looking ahead, my strategy includes maintaining Abcam's listing on NASDAQ and listing the Company on the Main Market of the London Stock Exchange. To support me with this process, I am pleased to announce that I have appointed Peel Hunt, a leading UK investment bank, as part of my advisory team. With the benefit of hindsight, I believe that leaving the LSE last year was misguided and led to a number of long-term UK shareholders becoming sellers over time. Abcam also benefitted from a scarcity value when listed in London with a broad and deep following of long-standing institutional shareholders. This dual listing approach aims to better cater to UK institutions and would take advantage of recently announced regulatory reforms in the UK, while also prioritising the maintenance of the important NASDAQ listing in the US.

 

Shareholder value creation will be at the heart of my strategy and I strongly believe in transparency and equality for all shareholders. I encourage shareholders to visit my website for further details of my campaign and to see updates on my plan for Abcam.

 

I URGE ALL SHAREHOLDERS TO VOTE AGAINST THIS PROPOSED TRANSACTION ON THE PROXY FORM. THIS IS AN OPPORTUNITY FOR SHAREHOLDERS TO SEND A CLEAR MESSAGE TO THE BOARD THAT THEY ARE DISSATISFIED WITH THE PROPOSED ACQUISITION AS WELL AS WITH THE COMPANY’S GOVERNANCE, EXECUTION AND COST CONTROL.

 

Yours sincerely,

 

Jonathan Milner”

 

Jonathan Milner

https://abcamfocus.com/

 

Investor contact

 

Alliance Advisors

Alliance Advisors LLC

T: +44 7733 265 198 / focusabcam@allianceadvisors.com

Michael Roper

 

 

 

 

Peel Hunt LLP

T: +44 (0) 20 7418 8900

Christopher Golden / James Steel

Sohail Akbar / Jock Maxwell Macdonald

 

International PR advisers

 

ICR Consilium (Europe)

T: +44 (0)20 3709 5700 / E: focusabcam@consilium-comms.com

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

ICR (US)

T: +1 646 677 1811 / E: FocusAbcam@icrinc.com

Dan McDermott

 

 

 

 

IMPORTANT ADDITIONAL INFORMATION

 

THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").

 

DR. MILNER IS PUBLISHING A PROXY STATEMENT AND ACCOMPANYING [WHITE] PROXY CARD TO BE USED TO SOLICIT VOTES AGAINST THE PROPOSED ACQUISITION OF ABCAM PLC (THE "COMPANY") BY DANAHER CORPORATION OR ONE OF ITS AFFILIATES AT $24 PER SHARE AT A MEETING OF THE SHAREHOLDERS CONVENED PURSUANT TO THE COMPANIES ACT 2006 (THE “COURT MEETING”).

 

DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE MADE AVAILABLE AT NO CHARGE ONLINE ON THE WEBSITE OF THE U.S. SECURITIES AND EXCHANGE COMMISSION AT WWW.SEC.GOV AND ON A WEBSITE HOSTED BY DR. MILNER TO PROVIDE INFORMATION TO SHAREHOLDERS ABOUT THE COURT MEETING AT WWW.ABCAMFOCUS.COM. HOLDERS OF COMPANY SECURITIES ALSO SHOULD RECEIVE COPIES OF THE PROXY STATEMENT AND PROXY CARD BY MAIL, AND COPIES WILL BE PROVIDED AT NO CHARGE UPON REQUEST MADE TO DR. MILNER’S PROXY SOLICITOR, ALLIANCE ADVISORS, , BY EMAIL TO FOCUSABCAM@ALLIANCEADVISORS.COM OR BY PHONE TO 877-777-8211 FROM NORTH AMERICA OR TO 0800-102- 6998 FROM ELSEWHERE.

 

THIS DOCUMENT IS FOR DISCUSSION AND INFORMATIONAL PURPOSES ONLY. THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF. DR. MILNER RESERVES THE RIGHT TO CHANGE ANY OF HIS OPINIONS EXPRESSED HEREIN AT ANY TIME AND FOR ANY REASON AND EXPRESSLY DISCLAIMS ANY OBLIGATION TO CORRECT, UPDATE OR REVISE THE INFORMATION CONTAINED HEREIN OR TO OTHERWISE PROVIDE ANY ADDITIONAL MATERIALS. SUBJECT TO THE FOREGOING, AND AS SET FORTH BELOW, DR. MILNER INTENDS TO MAKE AVAILABLE AT AN APPROPRIATE TIME ADDITIONAL INFORMATION ABOUT THE COURT MEETING INCLUDING HOW TO VOTE AT SUCH MEETING.

 

DR. MILNER HAS INVESTMENTS IN THE COMPANY WHICH ARE DISCLOSED IN THE PROXY STATEMENT AND OTHER PROXY MATERIALS, AND CONSEQUENTLY HAS A FINANCIAL INTEREST IN THE PROFITABILITY OF HIS POSITIONS IN THE COMPANY. ACCORDINGLY THIS DOCUMENT SHOULD NOT BE REGARDED AS IMPARTIAL. NOTHING IN THIS DOCUMENT SHOULD BE TAKEN AS ANY INDICATION OF DR. MILNER 'S CURRENT OR FUTURE TRADING OR VOTING INTENTIONS AND/OR ACTIVITIES WHICH MAY CHANGE AT ANY TIME.

 

CERTAIN INFORMATION IN THIS DOCUMENT IS BASED ON PUBLICLY AVAILABLE INFORMATION WITH RESPECT TO THE COMPANY, INCLUDING PUBLIC FILINGS AND DISCLOSURES MADE BY THE COMPANY AND OTHER SOURCES, AS WELL AS DR. MILNER'S ANALYSIS OF SUCH PUBLICLY AVAILABLE INFORMATION. DR. MILNER HAS RELIED UPON AND ASSUMED, WITHOUT INDEPENDENT VERIFICATION, THE ACCURACY AND COMPLETENESS OF SUCH INFORMATION, AND NO REPRESENTATION OR WARRANTY IS MADE THAT ANY SUCH DATA OR INFORMATION IS COMPLETE OR ACCURATE. DR. MILNER RECOGNISES THAT THERE MAY BE CONFIDENTIAL OR OTHERWISE NON-PUBLIC INFORMATION WITH RESPECT TO THE COMPANY THAT COULD ALTER THE OPINIONS OF DR. MILNER WERE SUCH INFORMATION KNOWN.

 

NO REPRESENTATION, WARRANTY OR UNDERTAKING, EXPRESS OR IMPLIED, IS GIVEN AND NO RESPONSIBILITY OR LIABILITY OR DUTY OF CARE IS OR WILL BE ACCEPTED BY DR. MILNER CONCERNING: (I) THIS DOCUMENT AND ITS CONTENTS, INCLUDING WHETHER THE INFORMATION AND OPINIONS CONTAINED HEREIN ARE ACCURATE, FAIR, COMPLETE OR CURRENT; (II) THE PROVISION OF ANY FURTHER INFORMATION, WHETHER BY WAY OF UPDATE TO THE INFORMATION AND OPINIONS CONTAINED IN THIS DOCUMENT OR OTHERWISE TO THE RECIPIENT AFTER THE DATE OF THIS DOCUMENT; OR (III) THAT DR. MILNER'S INVESTMENT PROCESSES OR INVESTMENT OBJECTIVES WILL OR ARE LIKELY TO BE ACHIEVED OR SUCCESSFUL OR THAT DR. MILNER'S INVESTMENTS WILL MAKE ANY PROFIT OR WILL NOT SUSTAIN LOSSES. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TO THE FULLEST EXTENT PERMITTED BY LAW, DR. MILNER WILL NOT BE RESPONSIBLE FOR ANY LOSSES, WHETHER DIRECT, INDIRECT OR CONSEQUENTIAL, INCLUDING LOSS OF PROFITS, DAMAGES, COSTS, CLAIMS OR EXPENSES RELATING TO OR ARISING FROM THE RECIPIENT'S OR ANY PERSON'S RELIANCE ON THIS DOCUMENT.

 

 

 

 

EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE INFORMATION AND OPINIONS INCLUDED IN THIS DOCUMENT CONSTITUTE FORWARD-LOOKING STATEMENTS, INCLUDING ESTIMATES AND PROJECTIONS PREPARED WITH RESPECT TO, AMONG OTHER THINGS, THE COMPANY'S ANTICIPATED OPERATING PERFORMANCE, THE VALUE OF THE COMPANY'S SECURITIES, DEBT OR ANY RELATED FINANCIAL INSTRUMENTS THAT ARE BASED UPON OR RELATE TO THE VALUE OF SECURITIES OF THE COMPANY (COLLECTIVELY, "COMPANY SECURITIES"), GENERAL ECONOMIC AND MARKET CONDITIONS AND OTHER FUTURE EVENTS. YOU SHOULD BE AWARE THAT ALL FORWARD-LOOKING STATEMENTS, ESTIMATES AND PROJECTIONS ARE INHERENTLY UNCERTAIN AND SUBJECT TO SIGNIFICANT ECONOMIC, COMPETITIVE, AND OTHER UNCERTAINTIES AND CONTINGENCIES AND HAVE BEEN INCLUDED SOLELY FOR ILLUSTRATIVE PURPOSES. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THE INFORMATION CONTAINED HEREIN DUE TO REASONS THAT MAY OR MAY NOT BE FORESEEABLE. THERE CAN BE NO ASSURANCE THAT THE COMPANY SECURITIES WILL TRADE AT THE PRICES THAT MAY BE IMPLIED HEREIN, AND THERE CAN BE NO ASSURANCE THAT ANY ESTIMATE, PROJECTION OR ASSUMPTION HEREIN IS, OR WILL BE PROVEN, CORRECT.

 

THIS DOCUMENT DOES NOT CONSTITUTE (A) AN OFFER OR INVITATION TO BUY OR SELL, OR A SOLICITATION OF AN OFFER TO BUY OR SELL, ANY SECURITY OR OTHER FINANCIAL INSTRUMENT AND NO LEGAL RELATIONS SHALL BE CREATED BY ITS ISSUE, (B) A "FINANCIAL PROMOTION" FOR THE PURPOSES OF THE FINANCIAL SERVICES AND MARKETS ACT 2000, (C) "INVESTMENT ADVICE" AS DEFINED BY THE FCA HANDBOOK, (D) "INVESTMENT RESEARCH" AS DEFINED BY THE FCA HANDBOOK, OR (E) AN "INVESTMENT RECOMMENDATION" AS DEFINED BY REGULATION (EU) 596/2014 AND BY REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF U.K. DOMESTIC LAW BY VIRTUE OF SECTION 3 OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA 2018") INCLUDING AS AMENDED BY REGULATIONS ISSUED UNDER SECTION 8 OF EUWA 2018. THIS DOCUMENT IS NOT (AND MAY NOT BE CONSTRUED TO BE) LEGAL, TAX, INVESTMENT, FINANCIAL OR OTHER ADVICE. EACH RECIPIENT SHOULD CONSULT THEIR OWN LEGAL COUNSEL AND TAX AND FINANCIAL ADVISERS AS TO LEGAL AND OTHER MATTERS CONCERNING THE INFORMATION CONTAINED HEREIN. THIS DOCUMENT DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION THAT MAY BE RELEVANT TO AN EVALUATION OF THE COMPANY, COMPANY SECURITIES OR THE MATTERS DESCRIBED HEREIN.

 

NO AGREEMENT, COMMITMENT, UNDERSTANDING OR OTHER LEGAL RELATIONSHIP EXISTS OR MAY BE DEEMED TO EXIST BETWEEN OR AMONG DR. MILNER AND ANY OTHER PERSON BY VIRTUE OF FURNISHING THIS DOCUMENT. DR. MILNER IS NOT ACTING FOR OR ON BEHALF OF, AND IS NOT PROVIDING ANY ADVICE OR SERVICE TO, ANY RECIPIENT OF THIS DOCUMENT. DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT. BEFORE DETERMINING ON ANY COURSE OF ACTION, ANY RECIPIENT SHOULD CONSIDER ANY ASSOCIATED RISKS AND CONSEQUENCES AND CONSULT WITH ITS OWN INDEPENDENT ADVISORS AS IT DEEMS NECESSARY.

 

DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN. ANY SUCH STATEMENTS OR INFORMATION SHOULD NOT BE VIEWED AS INDICATING THE SUPPORT OF SUCH THIRD PARTY FOR THE VIEWS EXPRESSED HEREIN. ALL TRADEMARKS AND TRADE NAMES USED HEREIN ARE THE EXCLUSIVE PROPERTY OF THEIR RESPECTIVE OWNERS.

 

 

 

Abcam (CE) (USOTC:ABCZF)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Abcam (CE).
Abcam (CE) (USOTC:ABCZF)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Abcam (CE).